TARS (Tarsus Pharmaceuticals) LT-Debt-to-Total-Asset : 0.19 (As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Tarsus Pharmaceuticals LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Tarsus Pharmaceuticals's long-term debt to total assests ratio for the quarter that ended in Dec. 2024 was 0.19.

Tarsus Pharmaceuticals's long-term debt to total assets ratio increased from Dec. 2023 (0.11) to Dec. 2024 (0.19). It may suggest that Tarsus Pharmaceuticals is progressively becoming more dependent on debt to grow their business.

Tarsus Pharmaceuticals LT-Debt-to-Total-Asset Historical Data

The historical data trend for Tarsus Pharmaceuticals's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tarsus Pharmaceuticals LT-Debt-to-Total-Asset Chart

Tarsus Pharmaceuticals Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.09

0.11

0.19

Tarsus Pharmaceuticals Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.11	0.09	0.19	0.19	0.19

Tarsus Pharmaceuticals LT-Debt-to-Total-Asset Calculation

Tarsus Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (A: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2024 )	/	Total Assets (A: Dec. 2024 )
	=	71.845	/	376.991
	=	0.19

Tarsus Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (Q: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2024 )	/	Total Assets (Q: Dec. 2024 )
	=	71.845	/	376.991
	=	0.19

Tarsus Pharmaceuticals (NAS:TARS) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Tarsus Pharmaceuticals LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Tarsus Pharmaceuticals's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Tarsus Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tarsus Pharmaceuticals Inc (NAS:TARS) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

15440 Laguna Canyon Road, Suite 160, Irvine, CA, USA, 92618

Website

https://www.tarsusrx.com

Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.

Executives

Dianne C. Whitfield	officer: Chief Human Resources Officer	15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618
Bryan Wahl	officer: General Counsel	15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618
Seshadri Neervannan	officer: Chief Operating Officer	15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618
Bobak R. Azamian	director, 10 percent owner, officer: President and CEO	15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618
Aziz Mottiwala	officer: Chief Commercial Officer	233 WILSHIRE BOULEVARD, SUITE 280, SANTA MONICA CA 90401
Jeffrey S Farrow	officer: See Remarks	TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080
Link William J Phd	director	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Jose M. Trevejo	officer: Chief Medical Officer	C/O TARSUS PHARMACEUTICALS, INC., 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618
Andrew D. Goldberg	director	15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618
Elizabeth Yeu Lin	director	25651 ATLANTIC OCEAN DRIVE, LAKE FOREST CA 92630
Leonard M. Greenstein	officer: Chief Financial Officer	24562 BELGREEN PLACE, LAKE FOREST CA 92630
Mark J. Holdbrook	officer: V.P., Clinical Affairs	15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618
Scott W Morrison	director	C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT SUITE 101, SOUTH SAN FRANCISCO CA 94080
Vivo Capital Fund Ix, L.p.	10 percent owner	192 LYTTON AVENUE, PALO ALTO CA 94301
Michael Ackermann	director, 10 percent owner	202 CARNEGIE CENTER, SUITE 109, PRINCETON NJ 08540